CBH Health — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$4,893	2
2023	Research	$78,603	3
2022	Research	$68,142	4
2021	Research	$195,141	4
2020	Research	$18,746	2

Breakdown

Who paid Research payments · program years 2020–2025

Biogen, Inc. $149,722 4 payments
Merck Sharp & Dohme Corporation $128,712 7 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $77,711 2 payments
H. Lundbeck A S $5,670 1 payment
Sage Therapeutics, Inc. $3,710 1 payment

Studies the money was for Research payments · program years 2020–2025

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $145,575 2 payments
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $81,203 4 payments
Connex X $72,898 1 payment
A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression $47,429 2 payments
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia $5,670 1 payment
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) $4,813 1 payment
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) $4,147 2 payments
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI) $3,710 1 payment
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $80 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.